SERM Ospemifene Reduces Vestibular Nerve Fiber SensitivityA newly published pilot study is the first to show that the selective estrogen receptor modulator (SERM) ospemifene effectively normalizes vestibular innervation sensitivity, in addition to confirming that it relieves postmenopausal vestibular signs and symptoms.
Study: Clinical trials indicate positive results for Zika vaccineThree Phase 1 human clinical trials evaluating the efficacy of an Army-developed Zika purified inactivated virus (ZPIV) vaccine have shown it to be safe and well tolerated, according to a recent study. Plus: Another study has found an association between postmenopausal vasomotor symptoms (VMS), including hot flashes and night sweats, and elevated risk of diabetes.
Study: Annual ob/gyn visits decliningResearchers note that the number of women who annually visit an ob/gyn has steadily declined since 2000. Plus: MAb may reduce risk of fracture in women with osteoporosis. Also, a study shows that postmenopausal hormone therapy is not associated with risk of all-cause, cardiovascular, or total cancer mortality.
Combination pack approved for breast cancer treatmentFDA approves ribociclib plus letrozole to treat a subset of advanced breast cancer patients.
FDA approves Ibrance to treat metastatic breast cancerIbrance is a potent and selective inhibitor of cyclin-dependent kinases (CDKs) 4 and 6, which complex with a regulatory protein, called cyclin, to control cancer cell cycling. The FDA has approved it for use in the treatment of metastatic breast cancer.
NSAID use can reduce breast cancer recurrence in overweight, obese womenOverweight and obese postmenopausal breast cancer patients taking aromatase inhibitors may gain a significant benefit by adding nonsteroidal anti-inflammatory drugs (NSAIDs) to their treatment, according to a study published in the August 14 issue of Cancer Research.
Sugary beverages linked to endometrial cancerDrinking sugar-sweetened beverages boosts calories—and also risk of estrogen-dependent type 1 endometrial cancer—according to a study of more than 23,000 postmenopausal women. Published in Cancer Epidemiology, Biomarkers & Prevention, the report found no similar link with sugar-free drinks.
Long-term use of CCBs may increase risk of breast cancerLong-term use of calcium-channel blockers (CCBs) may increase the risk of breast cancer in postmenopausal women, but additional research is needed to confirm, according to a study in JAMA Internal Medicine, published online August 5.